Premium
Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma
Author(s) -
Rosen Daniel G.,
Yang Gong,
Deavers Michael T.,
Malpica Anais,
Kavanagh John J.,
Mills Gordon B.,
Liu Jinsong
Publication year - 2006
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.21767
Subject(s) - medicine , cyclin e , cyclin b1 , carcinogenesis , cancer research , oncology , ovarian cancer , carcinoma , cancer , tumor progression , cyclin , pathology , cell cycle , cyclin dependent kinase 1
BACKGROUND Cyclins, cyclin dependent kinases (cdks), and their inhibitors act in combination to regulate progression through the cell cycle and often are dysregulated in carcinoma. The authors hypothesized that cyclin E plays an important role in ovarian carcinogenesis and that its overexpression may be an indicator of a poor prognosis. METHODS Immunohistochemical analysis of cyclin E expression was performed by image analysis in normal ovaries, cystadenomas, tumors of low malignant potential, and 405 primary ovarian carcinomas by using tissue microarray technology. RESULTS Overexpression of cyclin E was found in 63.2% of the samples and was associated with clear cell, poorly differentiated, and serous carcinoma ( P ≤ .001), high‐grade tumors ( P ≤ .001), late‐stage disease ( P = .002), age older than 60 years at the time of diagnosis ( P = .04), and suboptimal cytoreduction ( P = .001). A high percentage of cyclin E‐expressing cells was associated with a poor outcome in univariate and in multivariate analyses. In addition, cyclin E levels also reduced survival in the late‐stage disease group and in patients who underwent suboptimal debulking. CONCLUSIONS Cyclin E was identified as an independent prognostic factor in patients with ovarian carcinoma. The accumulation of cyclin E protein may be a late event in tumorigenesis and may contribute to disease progression in these patients. Cancer 2006. © 2006 American Cancer Society.